Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Gufic BioScience
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 224 | 237 | 231 |
| Expenses + | 176 | 165 | 161 | 167 | 166 | 174 | 179 | 190 | 199 | 198 |
| Operating Profit | 39 | 36 | 34 | 36 | 39 | 34 | 26 | 33 | 38 | 33 |
| OPM % | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 15% | 16% | 14% |
| Other Income + | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 1 |
| Interest | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 | 8 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 | 8 |
| Profit before tax | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 17 | 23 | 18 |
| Tax % | 25% | 25% | 26% | 26% | 26% | 26% | 27% | 24% | 26% | 30% |
| Net Profit + | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 13 | 17 | 12 |
| EPS in Rs | 2.39 | 2.22 | 2.00 | 2.08 | 2.17 | 1.93 | 0.77 | 1.30 | 1.68 | 1.24 |
Financials of Gufic BioScience
Annual income statement trend
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| Sales + | 807 | 820 | 897 |
| Expenses + | 657 | 684 | 767 |
| Operating Profit | 150 | 136 | 130 |
| OPM % | 19% | 17% | 15% |
| Other Income + | -0 | 4 | 4 |
| Interest | 17 | 25 | 36 |
| Depreciation | 17 | 21 | 31 |
| Profit before tax | 116 | 94 | 68 |
| Tax % | 26% | 26% | |
| Net Profit + | 86 | 70 | 50 |
| EPS in Rs | 8.59 | 6.95 | 4.99 |
| Dividend Payout % | 1% | 1% |
Financials of Gufic BioScience
Capital structure and asset base
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 10 | 10 | 10 |
| Reserves | 523 | 591 | 621 |
| Borrowings + | 333 | 336 | 369 |
| Other Liabilities + | 227 | 232 | 271 |
| Total Liabilities | 1,093 | 1,169 | 1,271 |
| Fixed Assets + | 159 | 506 | 495 |
| CWIP | 307 | 22 | 24 |
| Investments | 2 | 2 | 2 |
| Other Assets + | 625 | 640 | 750 |
| Total Assets | 1,093 | 1,169 | 1,271 |
Financials of Gufic BioScience
Operating, investing and financing cash movement
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Cash from Operating Activity + | -7 | 123 |
| Cash from Investing Activity + | -102 | -71 |
| Cash from Financing Activity + | 82 | -37 |
| Net Cash Flow | -27 | 15 |
| Free Cash Flow | -116 | 52 |
| CFO/OP | 13% | 107% |
Financials of Gufic BioScience
Working capital efficiency and return ratios
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 149 | 140 |
| Inventory Days | 188 | 211 |
| Days Payable | 156 | 155 |
| Cash Conversion Cycle | 181 | 197 |
| Working Capital Days | 97 | 93 |
| ROCE % | 13% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…